| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Special Articles |
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Texas Medical School (S.N.), Houston, Texas 77030; and the Department of Medicine, University of Southern California Medical School (M.G.R.-G., M.F.S.), Los Angeles, California 90033
Address all correspondence and requests for reprints to: Shahla Nader, M.D., Division of Reproductive Endocrinology, University of Texas Medical School, 6431 Fannin, Suite 3.036, Houston, Texas 77030.
Ovarian hyperandrogenism can be associated with insulin resistance, hyperinsulinemia, glucose intolerance, and obesity. High levels of the lipostatic hormone, leptin, have also been reported in this condition. The purpose of the present study was to examine the effect of an oral contraceptive (OC) of low androgenicity containing desogestrel on glucose tolerance in hyperandrogenic women and the impact of changes in androgenic/estrogenic status on leptin concentrations. Sixteen nondiabetic hyperandrogenic women, aged 29 ± 1 yr with a body mass index (BMI) of 36.8 ± 1.8 kg/m2, underwent an oral glucose tolerance test before and after 6 months of therapy with the OC. Free testosterone decreased and sex hormone-binding globulin increased after therapy (P < 0.001). Glucose tolerance deteriorated significantly, and two women developed diabetes. Body weight, BMI, and leptin did not change significantly. Leptin correlated with BMI before (r = 0.56; P = 0.02) and after (r = 0.51; P = 0.04) treatment, but not with glucose, insulin, total and free testosterone, or sex hormone-binding globulin before or after treatment. In conclusion, 1) glucose tolerance should be monitored in hyperandrogenic women using OC, even those of low androgenicity; and 2) changes in androgenic/estrogenic status had no effect on the leptin concentration, suggesting that its sexual dimorphism is not related to sex steroids.
This article has been cited by other articles:
![]() |
C. Meyer, B. P. McGrath, and H. J. Teede Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome Diabetes Care, March 1, 2007; 30(3): 471 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nader and E. Diamanti-Kandarakis Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis Hum. Reprod., February 1, 2007; 22(2): 317 - 322. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Legro, C. L. Gnatuk, A. R. Kunselman, and A. Dunaif Changes in Glucose Tolerance over Time in Women with Polycystic Ovary Syndrome: A Controlled Study J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3236 - 3242. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Vrbikova and D. Cibula Combined oral contraceptives in the treatment of polycystic ovary syndrome Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Rautio, J S Tapanainen, A Ruokonen, and L C Morin-Papunen Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome Eur. J. Endocrinol., February 1, 2005; 152(2): 269 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden Definitions of the Insulin Resistance Syndrome: The 1st World Congress on the Insulin Resistance Syndrome Diabetes Care, March 1, 2004; 27(3): 824 - 830. [Full Text] [PDF] |
||||
![]() |
D. S. Guzick Polycystic Ovary Syndrome Obstet. Gynecol., January 1, 2004; 103(1): 181 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Morin-Papunen, K. Rautio, A. Ruokonen, P. Hedberg, M. Puukka, and J. S. Tapanainen Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4649 - 4654. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cagnacci, A. M. Paoletti, A. Renzi, M. Orru, M. Pilloni, G. B. Melis, and A. Volpe Glucose Metabolism and Insulin Resistance in Women with Polycystic Ovary Syndrome during Therapy with Oral Contraceptives Containing Cyproterone Acetate or Desogestrel J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3621 - 3625. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC Diabetes Care, April 1, 2003; 26(4): 1297 - 1303. [Full Text] [PDF] |
||||
![]() |
J. E. Nestler Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Elter, G. Imir, and F. Durmusoglu Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study Hum. Reprod., July 1, 2002; 17(7): 1729 - 1737. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jovanovic Finally, It Is Our Turn! Diabetes Care, April 1, 2002; 25(4): 787 - 788. [Full Text] [PDF] |
||||
![]() |
L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, H. K. Martikainen, and J. S. Tapanainen Endocrine and Metabolic Effects of Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3161 - 3168. [Abstract] [Full Text] |
||||
![]() |
J. W. Newcomer, G. Selke, A. K. Melson, J. Gross, G. P. Vogler, and S. Dagogo-Jack Dose-Dependent Cortisol-Induced Increases in Plasma Leptin Concentration in Healthy Humans Arch Gen Psychiatry, November 1, 1998; 55(11): 995 - 1000. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |